AnnWillmanSilkMD

PubMed

• Changes in Merkel cell oncoprotein antibodies after radiation therapy in curatively treated Merkel cell carcinoma and association with recurrence.
  Kevin X Liu, Kee-Young Shin, Manisha Thakuria, Jonathan D Schoenfeld, Roy B Tishler
  Cancer. 2024-12-15
• Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic Implications.
  Tomoko Akaike, Manisha Thakuria, Ann W Silk, Daniel S Hippe, Song Youn Park
  Journal of Clinical Oncology. 2024-09-10
• A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, ...
  Brett G M Hughes, Alexander Guminski, Samantha Bowyer, Michael R Migden, Chrysalyne D Schmults
  Journal of the American Academy of Dermatology. 2024-09-07

Journal Articles

• Phase I Trial of ALT-803, a Novel Recombinant Interleukin-15 Complex, in Patients with Advanced Solid Tumors  
  Jeffrey S Miller, Shernan G Holtan, Sylvia M Lee, Chihiro Morishima, Ann W Silk, Clinical Cancer Research
• Clinical characterization of colitis arising from anti-PD-1 based therapy  
  Wang DY, Mooradian MJ, Kim DW, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk AW, Zhou A, Compton ML, Al-Rohil RN, Lee S, Voorhees AL, Ha L, McKee S, Norrell JT, Mehnert ..., OncoImmunol, 1/1/2018
• Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma  
  Weber J, Mandala M, Del Vecchio M, and the CheckMate 238 Collaborators (Silk AW), N Engl J Med, 1/1/2017
• Efficacy and Safety of High-Dose Interleukin-2 Treatment in Melanoma Patients with a History of Brain Metastases  
  Chandar A, Silk AW, Clark JI, Daniels GA, McDermott DF, Morse MA, Wong MKK, Stein M, Mehnert JM, Danish SF, Perritt J and HL Kaufman, J Targeted Ther, 1/1/2016
• Introducing Precision Immunology  
  Kaufman HL and Silk AW, Onc Live, 1/1/2015
• Ultrasound and physical examinations for obese patients � Reply  
  Silk AW, McTigue KM, JAMA, 1/1/2011
• Join now to see all

Books/Book Chapters

• Precision Radiation Oncology 
  Chapter: Combined effects of immunotherapy and radiation therapy. 
  Page 250 - 266Jhawar SR, Silk AWEditors: Haffty BG, Goyal S.2018
• Oncology Board Flash Review 
  Chapter: Ovarian cancer. 
  Page 318 - 326Silk AW, Buckanovich REditors: Worden FP, Khoriaty RN.2013
• Oncology Board Flash Review 
  Chapter: Esophageal cancer. 
  Page 215 - 220Silk AW, Hayman JEditors: Worden FP, Khoriaty RN.2013

Abstracts/Posters

• Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.
  Stein MN, Malhotra J, Malhotra U, Silk AW, Chan N, Rodriguez-Rodriguez L, Aisner J, Aiken R, Newman J, Sadimin E, Saunders T, Frankel M, Kareddula A, El-Deiry WS, Tara..., J Clin Oncol, 1/1/2018
• A Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carci...
  Silk AW, LeBoeuf NR, Rabinowits G, Puzanov I, Burgess MA, Devata S, Moore D, Goydos JS, Chen HX, Kaufman H, Zloza A, Mehnert JM, ASCO-SITC Clinical Immuno-Oncology Symposium; New Jersey Cancer Retreat, San Francisco, CA, 1/1/2018
• A Phase I Study to Evaluate the Safety of Trigriluzole (BHV-4157) in Combination with PD-1 Blocking Antibodies.
  Silk AW, Berman R, Coric V, Ruggiero L, Reitz AB, Shih W, Kane MP, Mehnert JM, Pelletier JC, Zloza A, Goydos JS, ASCO-SITC Clinical Immuno-Oncology Symposium; New Jersey Cancer Retreat, San Francisco, CA, 1/1/2018
• Phase I Study of E7046, a Novel PGE2-receptor Type 4 Inhibitor, in Patients with Advanced Solid Tumors: Clinical Results and Effects on Myeloid- and T-Lymphoid Cell-me...
  Silk AW, ASCO-SITC Clinical Immuno-Oncology Symposium, San Francisco, CA, 1/1/2018
• CAPRA: A Phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients.
  Silk AW, Kaufman HL, Gabrail N, Mehnert J, Bryan J, Norrell J, Haider A, Medina D, Bommareddy PK, Shafren D, Grose M and A Zloza, SITC Annual Meeting, National Harbor, MD, 1/1/2017
• Margolin K, Morishima C, Cheever MA, Lacroix A, Fling S, Holtan S, Jones M, Kaiser J, Silk AW, Lee S, Miller J, Rhode P, Rock A, Velcheti V, Wong HC, Ernstoff MS, SITC Annual Meeting, National Harbor, MD, 1/1/2017
• GRM1 to induce M-CSF and CCL2 expression to lead to an upregulation of M2 macrophages in melanoma.
  Li J, Wen Y, Jeong B, Shah R, Isola A, Silk AW, Chen S, Goydos JS, ASCO-SITC Clinical Immuno-Oncology Symposium, Orlando, FL, 1/1/2017
• Mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.
  Ganesan S, Bhanot G, Mehnert JM, Silk AW, Ross JS, Pavlick D, Ali SM, Markowski P, Kaufman H, Sullivan RJ, Lovly CM, Sosman JA, Johnson DB, Betigeri A, Subramanian K, ..., ASCO-SITC Clinical Immuno-Oncology Symposium, Orlando, FL, 1/1/2017
• Clinical presentation of immune-related colitis associated with PD-1 inhibitor monotherapy (MONO) and combination PD-1/CTLA-4 inhibitors (COMBO) in melanoma.
  Wang DY, Kim D, Shah NJ, Conry RM, Mehta R, Silk AW, Zhou A, Voorhees AL, McKee S, Mehnert J, Puzanov I, Gibney GT, Rapisuwon S, Eroglu Z, Johnson DB, ASCO Annual Meeting, Chicago, IL, 1/1/2017
• The Imipridone ONC201, a Selective DRD2 Antagonist, and Exerts Anticancer and Immunostimulatory Activity in advanced cancer patients.
  Stein MN, Chan N, Silk A, Malhotra J, Aisner J, Aiken R, Zloza A, El-Deiry WS, Newman J, Chesson C, Tarapore R, Stogniew M, Allen JE, Oster W, Saunders T, Yu B, Dicker..., ASCO Annual Meeting, Chicago, IL, 1/1/2017
• Financial impact of flat dosed (FD) monoclonal antibodies (MABs) at a single institution in 2016.
  Kane MP, Silk AW, Lee F, Auriemma P, Mehnert JM, ASCO Annual Meeting, Chicago, IL, 1/1/2017
• Novel Oncogenic BRAF Fusions and Impact on Targeted Therapies.
  Dolfi SC, Silk A, Paratala B, Petrosky W, Simhadri S, Kulkarni A, Ganesan S,Hirshfield KM, AACR Annual Meeting; New Jersey Cancer Retreat, Washington, DC, 1/1/2017
• Phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients: Interim results of the CAPRA clinical trial.
  Silk AW, Kaufman HL, Gabrail N, Mehnert J, Bryan J, Norrell J, Medina D, Bommareddy PK, Shafren D, Grose M Zloza A, AACR Annual Meeting, Washington, DC, 1/1/2017
• High response rates with combines BRAF and autophagy inhibition: results of two phase 1 trials.
  Gangadhar T, Ojha R, Murugan S, Schuchter L, Mitnick S, Mehnert J, Silk AW, Hernandez Aya L, Aleman T, Huang A, Linette G, Amaravadi RK, Society for Melanoma Research Annual Congress, Boston, MA, 1/1/2016
• Immune activation and prolonged benefit to avelumab (anti-PD-L1) therapy in a patient with metastatic EBV + gastric cancer.
  Panda A, Mehnert J, Hirshfield KM, Riedlinger G, Damare S, Saunders T, Sokol L, Stein S, Poplin E, Rodriguez L, Silk A, Chan N, Frankel M, Kane M, Malhotra J, Aisner J..., Society for Immunotherapy of Cancer Annual Meeting, National Harbor, MD, 1/1/2016
• Interim results of the CAPRA clinical trial: CAVATAK and pembrolizumab in advanced melanoma.
  Kaufman HL, Silk A, Mehnert J, Gabrail N, Bryan J, Medina D, Bommareddy PK, Shafren D, Grose M, Zloza A, Society for Immunotherapy of Cancer Annual Meeting, National Harbor, MD, 1/1/2016
• The oncolytic effect of talimogene laherparepvec (T-VEC) can be augmented by MEK inhibition in melanoma cell lines.
  Bommareddy PK, Kaufman HL, Zloza A, Kohlhapp F, Silk AW, Jhawar S, Paneque T, Society for Immunotherapy of Cancer Annual Meeting, National Harbor, MD, 1/1/2016
• Association of BRAF and NRAS Mutations with Favorable Response to Oncolytic Herpes Virus
  Silk AW, Second Annual Young Immuno-Oncology Investigators� Workshop, Houston, TX, 1/1/2016
• Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge"
  Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Kraut..., J Transl Med, 1/1/2016
• Treatment-associated rheumatoid arthritis in metastatic melanoma with complete response to pembrolizumab.
  Lee N, Silk A, Huzzy L, Dragert K, Beers S, Pindili D, Castrorao E, Ruppert M Kaufman HL, HL Sokol L, Mehnert JM, Society for Melanoma Research, San Francisco, CA, 1/1/2015
• Efficacy and Safety of High-Dose Interleukin-2 Treatment in Patients with a History of Brain Metastases from Renal Cell Carcinoma.
  Chandar A, Silk AW, Clark J, Daniels GA, McDermott DF, Morse MA, Wong MKK, Stein M, Mehnert JM, Danish SF, Aung S and HL Kaufman, Society for Immunotherapy of Cancer Annual Meeting, National Harbor, MD, 1/1/2015
• An Update on Oncolytic Virus Immunotherapy for the Treatment of Melanoma
  Silk AW, Melanoma Bridge Conference, Naples, Italy, 1/1/2015
• First-in-human dose escalation study of oral ONC201 in advanced solid tumors.
  Stein, MN, Mayer TM, Moss RA, Silk AW, Chan N, Haffty BG, DiPaola RS, Beckett Y, Bentlyewski E, Zheng L, Fang B, Allen J, JM Mehnert, American Society of Clinical Oncology Annual Meeting, Chicago, IL, 1/1/2015
• A pilot study of neoadjuvant cetuximab in locally advanced squamous cell carcinomas of skin (SCCS).
  Spencer KR, Kaveney AD, Goydos J, Kim S, Koshenkov VP, Goyal S, Khan AJ, Castrorao EM, Silk AW, Kaufman H, Huzzy L, Ruppert ML, Ganesan S, Mehnert JM, American Society of Clinical Oncology Annual Meeting, Chicago, IL, 1/1/2015
• A randomized phase II study of ipilimumab induction in patients with melanoma brain metastases receiving stereotactic radiosurgery.
  Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD, American Society of Clinical Oncology Annual Meeting, Chicago, IL, 1/1/2015
• Join now to see all

Lectures

• Oncolytic Viral Therapy in Melanoma and Merkel Cell Carcinoma: What�s Good for the Goose is Good for the Gander 
  University of Pittsburgh Medical Center, Pittsburgh, PA - 1/1/2018
• Oncolytic Viral Therapy 
  Rutgers Robert Wood Johnson Medical School - 1/1/2018
• Practical Radiology for Fellows 
  Rutgers Robert Wood Johnson Medical School - 1/1/2018
• Evening Highlights: How Will Today�s Presentations Impact Clinical Practice? 
  Orlando, FL - 1/1/2017
• Activation of a Clinical Trial 
  Rutgers Robert Wood Johnson Medical School - 1/1/2017
• Brain Metastases 
  Rutgers Robert Wood Johnson Medical School, 2015, 2017 - 1/1/2017
• Immunotherapy of Cancer 
  Rutgers Robert Wood Johnson Medical School, 2015, 2017 - 1/1/2017
• Skin Cancer Awareness Community Outreach 
  1/1/2017
• Response Evaluation in Clinical Trials RECIST and Immune-related Response Criteria 
  Rutgers Cancer Institute of New Jersey, New Brunswick, NJ - 1/1/2017
• Introduction to Clinical Trials 
  Rutgers Cancer Institute of New Jersey - 1/1/2016
• Supporting Your Immune System through Cancer Treatment 
  Rutgers Cancer Institute of New Jersey, New Brunswick, NJ - 1/1/2016
• Immunotherapy for the Treatment of Brain Metastases 
  Princeton, NJ - 1/1/2015
• Management of the Oncology Patient Receiving IL-2 
  Rutgers Cancer Institute of New Jersey, New Brunswick, NJ - 1/1/2015
• Challenging Cases of Newly Diagnosed and Recurrent Brain Metastases 
  San Francisco, CA - 1/1/2014
• Join now to see all